vs
Side-by-side financial comparison of STURM RUGER & CO INC (RGR) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $151.1M, roughly 2.0× STURM RUGER & CO INC). On growth, STURM RUGER & CO INC posted the faster year-over-year revenue change (3.6% vs -6.4%). Over the past eight quarters, STURM RUGER & CO INC's revenue compounded faster (5.1% CAGR vs 4.2%).
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
RGR vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $151.1M | $295.9M |
| Net Profit | — | $38.0M |
| Gross Margin | 17.8% | 64.6% |
| Operating Margin | 2.3% | 18.4% |
| Net Margin | — | 12.8% |
| Revenue YoY | 3.6% | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $0.22 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.1M | $295.9M | ||
| Q3 25 | $126.8M | — | ||
| Q2 25 | $132.5M | $317.0M | ||
| Q1 25 | $135.7M | $316.2M | ||
| Q4 24 | $145.8M | $297.0M | ||
| Q3 24 | $122.3M | $289.5M | ||
| Q2 24 | $130.8M | $306.1M | ||
| Q1 24 | $136.8M | $303.4M |
| Q4 25 | — | $38.0M | ||
| Q3 25 | $1.6M | — | ||
| Q2 25 | $-17.2M | $-17.7M | ||
| Q1 25 | $7.8M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $4.7M | $33.6M | ||
| Q2 24 | $8.3M | $40.6M | ||
| Q1 24 | $7.1M | $49.1M |
| Q4 25 | 17.8% | 64.6% | ||
| Q3 25 | 15.1% | — | ||
| Q2 25 | 3.9% | 62.7% | ||
| Q1 25 | 22.0% | 67.9% | ||
| Q4 24 | 22.8% | 65.3% | ||
| Q3 24 | 18.5% | 63.2% | ||
| Q2 24 | 22.3% | 66.4% | ||
| Q1 24 | 21.5% | 67.4% |
| Q4 25 | 2.3% | 18.4% | ||
| Q3 25 | -2.7% | — | ||
| Q2 25 | -15.6% | -7.5% | ||
| Q1 25 | 6.2% | 12.2% | ||
| Q4 24 | 7.8% | 16.0% | ||
| Q3 24 | 3.1% | 13.8% | ||
| Q2 24 | 6.9% | 15.0% | ||
| Q1 24 | 5.5% | 22.1% |
| Q4 25 | — | 12.8% | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | -13.0% | -5.6% | ||
| Q1 25 | 5.7% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 3.9% | 11.6% | ||
| Q2 24 | 6.3% | 13.3% | ||
| Q1 24 | 5.2% | 16.2% |
| Q4 25 | $0.22 | $0.24 | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $-1.05 | $-0.11 | ||
| Q1 25 | $0.46 | $0.14 | ||
| Q4 24 | $0.62 | $0.22 | ||
| Q3 24 | $0.28 | $0.21 | ||
| Q2 24 | $0.47 | $0.26 | ||
| Q1 24 | $0.40 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $92.5M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $283.8M | $2.0B |
| Total Assets | $342.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.5M | $172.9M | ||
| Q3 25 | $80.8M | — | ||
| Q2 25 | $101.4M | $162.2M | ||
| Q1 25 | $108.3M | $140.7M | ||
| Q4 24 | $105.5M | $177.5M | ||
| Q3 24 | $96.0M | $187.5M | ||
| Q2 24 | $105.6M | $152.9M | ||
| Q1 24 | $115.3M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $283.8M | $2.0B | ||
| Q3 25 | $279.6M | — | ||
| Q2 25 | $289.3M | $1.9B | ||
| Q1 25 | $321.5M | $2.0B | ||
| Q4 24 | $319.6M | $2.1B | ||
| Q3 24 | $314.9M | $2.1B | ||
| Q2 24 | $321.5M | $2.1B | ||
| Q1 24 | $332.0M | $2.0B |
| Q4 25 | $342.0M | $2.5B | ||
| Q3 25 | $342.3M | — | ||
| Q2 25 | $349.5M | $2.6B | ||
| Q1 25 | $379.0M | $2.6B | ||
| Q4 24 | $384.0M | $2.7B | ||
| Q3 24 | $373.5M | $2.7B | ||
| Q2 24 | $376.7M | $2.7B | ||
| Q1 24 | $385.0M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.5M | — |
| Free Cash FlowOCF − Capex | $12.3M | — |
| FCF MarginFCF / Revenue | 8.2% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $38.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.5M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $14.7M | $98.2M | ||
| Q1 25 | $11.1M | $41.1M | ||
| Q4 24 | $20.0M | $84.3M | ||
| Q3 24 | $9.4M | $63.9M | ||
| Q2 24 | $18.7M | $75.5M | ||
| Q1 24 | $7.3M | $81.0M |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $9.1M | $93.3M | ||
| Q1 25 | $10.0M | $31.0M | ||
| Q4 24 | $16.4M | $77.5M | ||
| Q3 24 | $2.6M | $54.7M | ||
| Q2 24 | $10.1M | $57.5M | ||
| Q1 24 | $5.6M | $64.5M |
| Q4 25 | 8.2% | — | ||
| Q3 25 | 5.5% | — | ||
| Q2 25 | 6.9% | 29.4% | ||
| Q1 25 | 7.4% | 9.8% | ||
| Q4 24 | 11.2% | 26.1% | ||
| Q3 24 | 2.1% | 18.9% | ||
| Q2 24 | 7.7% | 18.8% | ||
| Q1 24 | 4.1% | 21.3% |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.2% | 1.5% | ||
| Q1 25 | 0.8% | 3.2% | ||
| Q4 24 | 2.5% | 2.3% | ||
| Q3 24 | 5.5% | 3.2% | ||
| Q2 24 | 6.6% | 5.9% | ||
| Q1 24 | 1.3% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | 8.15× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.43× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 1.98× | 1.90× | ||
| Q2 24 | 2.27× | 1.86× | ||
| Q1 24 | 1.04× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
